Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
95.41
Oct 23 • 3:59 PM ET Dollar change-1.18 Percentage change(-1.22%)
Aftermarket Close
94.75
Aftermarket • 7:39 PM ET Dollar change-0.66 Percentage change(-0.69%)
Oct 22, 7:05 AMMedtronic reports positive real-world data showing strong safety and efficacy for Sphere-9 and PulseSelect in atrial fibrillation and ventricular tachycardia
Index
S&P 500
Market Cap
122.05B
Enterprise Value
142.00B
Income
5.23B
Sales
37.54B
Book/sh
39.24
Cash/sh
6.89
Employees
95000
IPO
Nov 21, 1977
P/E
23.49
Forward P/E
14.92
PEG
1.93
P/S
3.25
P/B
2.43
P/C
13.84
P/FCF
19.90
EV/EBITDA
13.63
EV/Sales
3.78
Quick Ratio
1.54
Current Ratio
2.07
Debt/Eq
0.56
LT Debt/Eq
0.51
Option/Short
Yes / Yes
EPS (ttm)
4.06
EPS next Y
6.39
EPS next Q
1.33
EPS this Y
8.09%
EPS next Y
6.99%
EPS next 5Y
7.72%
EPS past 3/5Y
9.75% 6.95%
Sales past 3/5Y
5.21% 3.84%
EPS Y/Y TTM
12.28%
Sales Y/Y TTM
9.77%
EPS Q/Q
41.57%
Sales Q/Q
13.73%
Insider Own
0.09%
Insider Trans
-5.67%
Inst Own
88.85%
Inst Trans
-1.94%
ROA
5.68%
ROE
10.66%
ROIC
6.90%
Gross Margin
60.56%
Oper. Margin
19.93%
Profit Margin
13.93%
SMA20
5.18%
SMA50
4.43%
SMA200
8.15%
Trades
Shs Outstand
1.28B
Shs Float
1.28B
52W High
106.33 -10.27%
52W Low
73.31 30.15%
Volatility
2.42% 2.56%
ATR (14)
2.40
RSI (14)
59.78
Beta
0.60
Rel Volume
0.37
Avg Volume
16.28M
Volume
6,009,108
Perf Week
0.70%
Perf Month
7.80%
Perf Quarter
13.29%
Perf Half Y
14.51%
Perf YTD
-0.68%
Perf Year
1.27%
Perf 3Y
31.80%
Perf 5Y
-22.49%
Perf 10Y
13.71%
Prev Close
96.59
Price
95.41
Change %
-1.22%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Marinaro MichaelEVP, Pres MedSurg and AmericasOct 15 '26Sale96.0010,4201,000,320105,916Oct 16 06:02 PM
Martha GeoffreyChairman and CEOOct 15 '26Sale95.0050,0004,750,000277,866Oct 16 06:00 PM
Marinaro MichaelOfficerOct 15 '26Proposed Sale96.0010,4201,000,320Oct 15 05:00 PM
Martha GeoffreyOfficerOct 15 '26Proposed Sale95.0050,0004,750,000Oct 15 09:41 AM
KIIL HARRY SKIPEVP & President CardiovascularSep 16 '26Sale93.651,483138,88342,186Sep 17 04:17 PM
KIIL HARRY SKIPOfficerSep 16 '26Proposed Sale93.651,483138,889Sep 16 02:37 PM
Walter Matthew R.SVP, Chief HR OfficerJul 08 '26Sale83.153,102257,93135,694Jul 09 04:26 PM
Walter Matthew R.OfficerJul 08 '26Proposed Sale83.153,102257,931Jul 08 10:15 AM
KIIL HARRY SKIPEVP & President CardiovascularJun 08 '26Sale80.444,189336,96537,227Jun 09 04:16 PM
KIIL HARRY SKIPOfficerJun 08 '26Proposed Sale80.444,189336,965Jun 08 02:34 PM
Walter Matthew R.SVP, Chief HR OfficerMay 26 '26Option Exercise0.009,149041,529May 28 04:26 PM
Wall Brett A.EVP & Pres NeuroscienceMay 26 '26Option Exercise0.0026,907082,183May 28 04:26 PM
Martha GeoffreyChairman and CEOMay 26 '26Option Exercise0.0094,9630343,099May 28 04:25 PM
Marinaro MichaelEVP, Pres MedSurg and AmericasMay 26 '26Option Exercise0.0018,994070,593May 28 04:25 PM
KIIL HARRY SKIPEVP & President CardiovascularMay 26 '26Option Exercise0.0015,195048,233May 28 04:25 PM
Blomquist Denise L.Chief Accounting OfficerMay 26 '26Option Exercise0.001,712014,974May 28 04:24 PM
KIIL HARRY SKIPEVP & President CardiovascularFeb 19 '26Option Exercise90.9050,8764,624,51285,292Feb 26 05:48 PM
KIIL HARRY SKIPEVP & President CardiovascularFeb 19 '26Sale97.7152,5245,132,21732,768Feb 26 05:48 PM
KIIL HARRY SKIPOfficerFeb 19 '26Proposed Sale97.7152,5245,132,217Feb 19 03:19 PM
Smith Gregory LEVP Global Ops & Supply ChainNov 19 '25Sale101.9530,0003,058,45146,016Nov 21 04:13 PM
Smith Gregory LOfficerNov 19 '25Proposed Sale101.9530,0003,058,452Nov 19 11:05 AM
Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Galway, Ireland.
Chairman of the Board & CEOMr. Geoffrey Straub Martha
SVP & Chief Operations and Supply Chain OfficerMr. Rogerio Branco
VPMs. Denise L. Blomquist
M.Sc.Dr. Laura Mauri M.D.
Vice President & Head of Investor RelationsMs. Ingrid Goldberg